Join Growin Stock Community!

國璽幹細胞6704.TW Overview

TW StockBiotech. & Medical
(No presentation for 6704)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

國璽幹細胞（6704）Overall Performance

國璽幹細胞（6704）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

國璽幹細胞（6704） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

國璽幹細胞（6704）Key Information

國璽幹細胞（6704）Profile

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell medicines for patients with unmet medical needs. The company's products under development include GXHPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, a novel autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. It is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.

國璽幹細胞（6704）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.65
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7.16
PB Ratio
3.73
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
69.06%
Net Margin
-48.52%
Revenue Growth (YoY)
-20.19%
Profit Growth (YoY)
-36.00%
3-Year Revenue Growth
12.45%
3-Year Profit Growth
7.53%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.65
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
7.16
PB Ratio
3.73
Price-to-FCF
-
Gross Margin
69.06%
Net Margin
-48.52%
Revenue Growth (YoY)
-20.19%
Profit Growth (YoY)
-36.00%
3-Year Revenue Growth
12.45%
3-Year Profit Growth
7.53%
default symbol

6704

國璽幹細胞

24.35D

3.08%

(0.03)

  • When is 6704's latest earnings report released?

    The most recent financial report for 國璽幹細胞 (6704) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6704's short-term business performance and financial health. For the latest updates on 6704's earnings releases, visit this page regularly.

  • How much cash does 6704 have?

    At the end of the period, 國璽幹細胞 (6704) held Total Cash and Cash Equivalents of 181.82M, accounting for 0.18 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6704 go with three margins increasing?

    In the latest report, 國璽幹細胞 (6704) did not achieve the “three margins increasing” benchmark, with a gross margin of 70.26%%, operating margin of -33.46%%, and net margin of -36.98%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6704's profit trajectory and future growth potential.